Leukemia, Myeloid, Acute — Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
Citation(s)
Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia